Declarations of interest Thorax: first published as 10.1136/thoraxjnl-2016-209333.464 on 15 November 2016. Downloaded from Declarations of Interest mittee membership: Actelion Pharmaceuticals Ltd. L Di Scala: Employee Actelion Pharmaceuticals Ltd. N Galié: Consulting fees/honoraria: Actelion Pharmaceuticals S34 EFFECT OF 8 AND 12 WEEKS’ ONCE-DAILY TIOTROPIUM Ltd, Bayer HealthCare, GlaxoSmithKline, Pfizer. Steering Com- AND OLODATEROL, ALONE AND COMBINED WITH mittee membership: Actelion Pharmaceuticals Ltd. EXERCISE TRAINING, ON EXERCISE ENDURANCE HA Ghofrani: Consulting fees/honoraria: Actelion Pharma- DURING WALKING IN PATIENTS WITH COPD ceuticals Ltd, Bayer HealthCare, Gilead Sciences Inc, GlaxoS- mithKline, Merck & Co, Novartis Corporation, Pfizer Inc. 10.1136/thoraxjnl-2016-209333.464 Steering Committee membership: Actelion Pharmaceuticals Ltd, Bayer HealthCare, Gilead Sciences Inc, GlaxoSmithKline, Merck T Troosters has received grants from Innovative Medicines Initia- & Co, Novartis Corporation, Pfizer Inc. tive Joint Undertaking and speaker fees from Boehringer Ingel- MM Hoeper: Consulting fees/honoraria: Actelion Pharma- heim and GlaxoSmithKline. ceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, Pfizer, Gilead J Bourbeau has received grants from the Canadian Institute of Sciences. Steering Committee membership: Actelion Pharmaceuti- Health Research R&D collaborative programme (AstraZeneca, cals Ltd. Boehringer Ingelheim, GlaxoSmithKline, Merck, Nycomed, I Lang: Consulting fees/honoraria: Actelion Pharmaceuticals Novartis), Canadian Respiratory Research Network, Respiratory Ltd, Bayer HealthCare, GlaxoSmithKline, Novartis Corporation, Health Network of the FRQS and Research Institute of the United Therapeutics. Steering Committee membership: Actelion MUHC, and an educational grant from GlaxoSmithKline. Pharmaceuticals Ltd. F Maltais has received grants from Boehringer Ingelheim, V McLaughlin: Consulting fees/honoraria: Actelion Pharma- GlaxoSmithKline, AstraZeneca, Nycomed and Pfizer, personal ceuticals Ltd, Bayer HealthCare, Gilead Sciences Inc, United fees from Boehringer Ingelheim, GlaxoSmithKline and Novartis, Therapeutics, Ikaria, Novartis. Steering Committee membership: and other financial support from GlaxoSmithKline. Actelion Pharmaceuticals Ltd, Bayer HealthCare, Gilead Sciences N Leidy is employed by Evidera, a health-care research firm Inc, United Therapeutics, Ikaria. that provides consulting and other research services to pharma- R Preiss: Employee Actelion Pharmaceuticals Ltd. LJ Rubin: ceutical and other organisations including the study sponsor. Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Arena D Erzen, D De Sousa, L Korducki and A Hamilton are Pharmaceuticals, GeNO Pharmaceuticals, Lung Biotechnology, employees of Boehringer Ingelheim Pharma GmbH & Co. KG. Gilead Sciences Inc, United Therapeutics. Steering Committee KL Lavoie reports personal fees from Boehringer Ingelheim membership: Actelion Pharmaceuticals Ltd. for personnel training as well as a grant from AbbVie and per- G Simonneau: Consulting fees/honoraria: Actelion Pharma- sonal fees from Bayer, Janssen, Novarits, AbbVie, Mundipharma ceuticals Ltd, Bayer HealthCare, Eli Lilly & Co, GlaxoSmithK- and Almirall. line, Novartis Corporation, Pfizer Inc. Steering Committee W Janssens has no conflict of interest to report. membership: Actelion Pharmaceuticals Ltd. O Sitbon: Consulting fees/honoraria: Actelion Pharmaceuticals Ltd, Bayer HealthCare, GlaxoSmithKline, Pfizer Inc, United Therapeutics. Steering Com- mittee membership: Actelion Pharmaceuticals Ltd. http://thorax.bmj.com/ S109 TARGETING THE PROSTACYCLIN PATHWAY IN THE TREATMENT OF CONNECTIVE TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM THE RANDOMISED CONTROLLED S112 LONG-TERM SAFETY AND EFFICACY OF IVACAFTOR IN GRIPHON TRIAL WITH SELEXIPAG PEDIATRIC PATIENTS AGED 2-5 YEARS WITH CYSTIC FIBROSIS AND A CFTR GATING MUTATION 10.1136/thoraxjnl-2016-209333.465 on September 27, 2021 by guest. Protected copyright. 10.1136/thoraxjnl-2016-209333.466 The GRIPHON study was sponsored by Actelion Pharmaceuticals Ltd. JC Davies has served on advisory boards, undertaken educational G Coghlan: Consulting fees: Actelion Pharmaceuticals Ltd, activities, and served as national/site principal investigator for tri- Bayer HealthCare, GlaxoSmithKline, GenenTech, United Thera- als, for which her institution has received funding from Vertex peutics. Speaker’s honoraria and research grants: Actelion Phar- Pharmaceuticals Incorporated. maceuticals Ltd, GlaxoSmithKline, Bayer HealthCare, United S Robertson is an employee of Vertex Pharmaceuticals Incor- Therapeutics. porated and may own stock or stock options in that company. S Gaine: Consulting fees/honoraria: Actelion Pharmaceuticals J Cooke is an employee of Vertex Pharmaceuticals Incorpo- Ltd, Bayer HealthCare, GlaxoSmithKline, United Therapeutics, rated and may own stock or stock options in that company. Novartis, Pfizer. Steering Committee membership: Actelion Phar- M Higgins is an employee of Vertex Pharmaceuticals Incorpo- maceuticals Ltd, GlaxoSmithKline, United Therapeutics, rated and my own stock or stock options in that company. Novartis. M Rosenfeld: has served as a national and site investigator for R Channick: Consulting fees/honoraria: Actelion Pharmaceuti- trials and as a consultant, for which her institution received fund- cals Ltd, Bayer HealthCare, United Therapeutics. Steering Com- ing from Vertex Pharmaceuticals Incorporated. A270 Thorax 2016;71(Suppl 3):A1–A288.